[{"address1": "451 D Street", "address2": "5th Floor Suite 501", "city": "Boston", "state": "MA", "zip": "02210", "country": "United States", "phone": "857-209-0050", "website": "https://elicio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops a pipeline of novel immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node\u0096targeted AMP peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company is also developing ELI-007, a multivalent lymph node\u0096targeted AMP peptide vaccine to target mutant v-raf murine sarcoma viral oncogene homolog B1 gene mutations found in solid tumors; and ELI-008, a multivalent lymph node\u0096targeted AMP peptide vaccine to target p53 hotspot mutations. The company is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 32, "auditRisk": 9, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1717200000, "maxAge": 86400, "priceHint": 2, "previousClose": 6.62, "open": 6.78, "dayLow": 6.31, "dayHigh": 7.48, "regularMarketPreviousClose": 6.62, "regularMarketOpen": 6.78, "regularMarketDayLow": 6.31, "regularMarketDayHigh": 7.48, "forwardPE": -2.1830065, "volume": 45468, "regularMarketVolume": 45468, "averageVolume": 48133, "averageVolume10days": 28510, "averageDailyVolume10Day": 28510, "marketCap": 68605600, "fiftyTwoWeekLow": 2.96, "fiftyTwoWeekHigh": 11.45, "fiftyDayAverage": 8.739, "twoHundredDayAverage": 6.8488, "currency": "USD", "enterpriseValue": 63327944, "floatShares": 5425847, "sharesOutstanding": 10270300, "sharesShort": 90442, "sharesShortPriorMonth": 61907, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0088, "heldPercentInsiders": 0.29513, "heldPercentInstitutions": 0.04042, "shortRatio": 1.96, "shortPercentOfFloat": 0.0112, "impliedSharesOutstanding": 10270300, "bookValue": 0.477, "priceToBook": 14.004192, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -38993000, "trailingEps": -3.82, "forwardEps": -3.06, "lastSplitFactor": "1:10", "lastSplitDate": 1685664000, "enterpriseToEbitda": -1.674, "52WeekChange": -0.31836736, "SandP52WeekChange": 0.26238096, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "ELTX", "underlyingSymbol": "ELTX", "shortName": "Elicio Therapeutics, Inc.", "longName": "Elicio Therapeutics, Inc.", "firstTradeDateEpochUtc": 1612535400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f5a7063e-a200-3645-afdf-a5955dd38a4c", "messageBoardId": "finmb_214936128", "gmtOffSetMilliseconds": -14400000, "currentPrice": 6.68, "targetHighPrice": 10.0, "targetLowPrice": 10.0, "targetMeanPrice": 10.0, "targetMedianPrice": 10.0, "recommendationMean": 2.5, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 11853000, "totalCashPerShare": 1.156, "ebitda": -37827000, "totalDebt": 6672000, "quickRatio": 1.992, "currentRatio": 2.374, "debtToEquity": 137.002, "returnOnAssets": -0.95538, "returnOnEquity": -12.88174, "freeCashflow": -20728088, "operatingCashflow": -36677000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]